ASCO 2026 BlissBio将于2026年ASCO年会上公布BB-1701联合信迪利单抗II期初步结果-动脉网

ASCO 2026 | BlissBio to Present Preliminary Phase II Results of BB-1701 Combined with Sintilimab at 2026 ASCO Annual Meeting

百力司康等信源发布 2026-06-02 11:04



可切换为仅中文







HANGZHOU, China, May 30, 2026 – BlissBio announces today that a poster will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, showing preliminary results from a Phase II study evaluating the safety and efficacy of BB-1701 in combination with sintilimab in patients with locally advanced or metastatic HER2 low-expressing breast cancer or HER2-mutated non-small cell lung cancer (NSCLC).

中国杭州，2026年5月30日——BlissBio今日宣布，将在2026年美国临床肿瘤学会（ASCO）年会上展示一项壁报，内容为一项II期临床研究的初步结果。该研究评估了BB-1701联合信迪利单抗治疗局部晚期或转移性HER2低表达乳腺癌或HER2突变型非小细胞肺癌（NSCLC）患者的安全性和有效性。

The ASCO Annual Meeting will take place from May 29 to June 2, 2026, in Chicago, USA..

ASCO年会将于2026年5月29日至6月2日在美国芝加哥举行。

Title: A phase II study to evaluate the safety and efficacy of BB-1701 in combination with sintilimab in patients with HER2 expression or mutation in locally advanced/metastatic breast cancer or NSCLC.

标题：一项评估BB-1701联合信迪利单抗在HER2表达或突变的局部晚期/转移性乳腺癌或非小细胞肺癌患者中安全性和有效性的II期研究。

Abstract #: 2632

摘要编号：2632

Poster Bd #: 422

海报展板编号：422

Session Title: Developmental Therapeutics—Immunotherapy

专场主题：研发治疗学——免疫治疗

Session Time: 1:30 PM-4:30 PM on May 30, 2026 CDT

会议时间：2026年5月30日中部夏令时间（CDT）下午1:30-4:30

Media Inquiries

媒体垂询

Bliss Biopharmaceutical Co., Ltd.